Prestige Biologics Co Stock Current Valuation
| 334970 Stock | KRW 4,505 310.00 6.44% |
Valuation analysis of Prestige Biologics helps investors to measure Prestige Biologics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Prestige Biologics' price fluctuation is very steady at this time. Calculation of the real value of Prestige Biologics is based on 3 months time horizon. Increasing Prestige Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Prestige Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Prestige Stock. However, Prestige Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4505.0 | Real 4583.25 | Hype 4815.0 |
The real value of Prestige Stock, also known as its intrinsic value, is the underlying worth of Prestige Biologics Company, which is reflected in its stock price. It is based on Prestige Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Prestige Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Prestige Biologics Co helps investors to forecast how Prestige stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Prestige Biologics more accurately as focusing exclusively on Prestige Biologics' fundamentals will not take into account other important factors: Prestige Biologics Co Company Current Valuation Analysis
Prestige Biologics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Prestige Biologics Current Valuation | 555.64 B |
Most of Prestige Biologics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prestige Biologics Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Prestige Biologics Co has a Current Valuation of 555.64 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The current valuation for all Republic of Korea stocks is significantly lower than that of the firm.
Prestige Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prestige Biologics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Prestige Biologics could also be used in its relative valuation, which is a method of valuing Prestige Biologics by comparing valuation metrics of similar companies.Prestige Biologics is rated below average in current valuation category among its peers.
Prestige Fundamentals
| Return On Equity | -53.64 | |||
| Current Valuation | 555.64 B | |||
| Revenue | 3.23 B | |||
| Gross Profit | (2.88 M) | |||
| EBITDA | (12.84 B) | |||
| Net Income | (39.38 B) | |||
| Cash And Equivalents | 36.77 B | |||
| Total Debt | 71.54 B | |||
| Cash Flow From Operations | (25.87 B) | |||
| Market Capitalization | 198.91 B | |||
| Total Asset | 206.77 B | |||
| Z Score | 1.2 | |||
| Net Asset | 206.77 B |
About Prestige Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prestige Biologics Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prestige Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prestige Biologics Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Prestige Biologics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Prestige Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Prestige Biologics will appreciate offsetting losses from the drop in the long position's value.Moving together with Prestige Stock
| 0.67 | 207940 | Samsung Biologics | PairCorr |
| 0.87 | 326030 | Sk Biopharmaceuticals | PairCorr |
| 0.83 | 298380 | ABL Bio | PairCorr |
| 0.89 | 144510 | Green Cross Lab | PairCorr |
Moving against Prestige Stock
The ability to find closely correlated positions to Prestige Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Prestige Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Prestige Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Prestige Biologics Co to buy it.
The correlation of Prestige Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Prestige Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Prestige Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Prestige Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Prestige Stock
Prestige Biologics financial ratios help investors to determine whether Prestige Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prestige with respect to the benefits of owning Prestige Biologics security.